within Pharmacolibrary.Drugs.ATC.N;

model N05AH04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.09,
    Cl             = 8.666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.024166666666666666,
    Tlag           = 5.3999999999999995,            
    Vdp             = 0.0046,
    k12             = 10.3,
    k21             = 10.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AH04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Quetiapine is an atypical antipsychotic medication approved for the treatment of schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder. It acts mainly by antagonism of serotonin (5-HT2A) and dopamine (D2) receptors. Quetiapine is widely prescribed and remains in routine clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from healthy adult volunteers after single-dose oral administration.</p><h4>References</h4><ol><li><p>DeVane, CL, &amp; Nemeroff, CB (2001). Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. <i>Clinical pharmacokinetics</i> 40(7) 509–522. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200140070-00003&quot;>10.2165/00003088-200140070-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11510628/&quot;>https://pubmed.ncbi.nlm.nih.gov/11510628</a></p></li><li><p>Fukushi, R, et al., &amp; Takada, A (2020). Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression. <i>Clinical therapeutics</i> 42(6) 1067–1076.e2. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2020.04.006&quot;>10.1016/j.clinthera.2020.04.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32518042/&quot;>https://pubmed.ncbi.nlm.nih.gov/32518042</a></p></li><li><p>DeBattista, C, &amp; Schatzberg, AF (2024). The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology bulletin</i> 54(3) 8–59. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38993656/&quot;>https://pubmed.ncbi.nlm.nih.gov/38993656</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AH04;
